SUPPLEMENT
Q4 2024 — Non-GAAP reconciliations
Q4 2024PDF · 21 pages307 KB
DANAHER CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES AND SUPPLEMENTAL FORWARD-LOOKING INFORMATION THREE-MONTH PERIODS AND YEARS ENDED DECEMBER 31, 2024 AND DECEMBER 31, 2023 -- 1 of 21 -- TABLE OF CONTENTS Page 1 Sales Growth (Decline) by Segment, Core Sales Growth (Decline) by Segment 1 Forecasted Core Sales (Decline) Growth and Adjusted Operating Profit Margin 2 Segment Sales, Operating Profit and Adjusted Operating Profit 3 Non-GAAP Profitability Measures 7 Other Non-GAAP Adjusted P&L Measures 13 Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding 14 Operating Profit Margins and Year-Over-Year Core Operating Margin Changes 16 Cash Flow from Continuing Operations, Free Cash Flow from Continuing Operations, Operating Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Ratio and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Conversion Ratio 17 Statement Regarding Non-GAAP Measures FORWARD-LOOKING STATEMENTS DISCLOSURE Statements in this document that are not strictly historical, including any statements regarding anticipated performance for any fiscal period that has not been completed, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: unanticipated, further declines in demand for our COVID-19 related products, the impact of global health crises, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations and fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2023 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2024. These forward-looking statements speak only as of the date of this document (January 28, 2025) and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise. -- 2 of 21 -- % Change Three-Month Period Ended December 31, 2024 vs. Comparable 2023 Period Segments Total Company Biotechnology Life Sciences Diagnostics Total sales growth (decline) (GAAP) 2.0 % 6.5 % 5.5 % (3.0) % Impact of: Acquisitions (1.5) % — % (5.0) % — % Currency exchange rates 0.5 % 1.5 % 0.5 % 1.0 % Core sales growth (decline) (non-GAAP) 1.0 % 8.0 % 1.0 % (2.0) % % Change Year Ended December 31, 2024 vs. Comparable 2023 Period Segments Total Company Biotechnology Life Sciences Diagnostics Total sales growth (decline) (GAAP) — % (6.0) % 2.5 % 2.0 % Impact of: Acquisitions (2.0) % — % (6.0) % — % Currency exchange rates 0.5 % 1.5 % 1.5 % 1.0 % Core sales (decline) growth (non-GAAP) (1.5) % (4.5) % (2.0) % 3.0 % Forecasted Core Sales (Decline) Growth and Adjusted Operating Profit Margin The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines. Additionally, we do not reconcile forecasted adjusted operating profit margin (or components thereof) to the comparable GAAP measures because of the difficulty in estimating the other components (in addition to items identified in the prior sentence) such as investment gains and losses and asset impairments, which would be reflected in any forecasted GAAP operating profit. % Change Three-Month Period Ending March 28, 2025 vs. Comparable 2024 Period % Change Year Ending December 31, 2025 vs. Comparable 2024 Period Core sales (decline) growth (non-GAAP) -Low single digit ~3.0% Three-Month Period Ending March 28, 2025 Year Ending December 31, 2025 Adjusted operating profit margin (non-GAAP) ~26.5 % ~28.5 % DANAHER CORPORATION Sales Growth (Decline) by Segment, Core Sales Growth (Decline) by Segment 1 -- 3 of 21 -- Sales (GAAP) Biotechnology $ 1,869 $ 1,759 $ 6,759 $ 7,172 Life Sciences 2,032 1,930 7,329 7,141 Diagnostics 2,637 2,716 9,787 9,577 Total Company $ 6,538 $ 6,405 $ 23,875 $ 23,890 Operating Profit (GAAP) Biotechnology $ 508 $ 416 $ 1,685 $ 1,909 Life Sciences 376 235 879 1,209 Diagnostics 624 766 2,625 2,406 Other (83) (80) (326) (322) Total Company $ 1,425 $ 1,337 $ 4,863 $ 5,202 Amortization of Intangible Assets (GAAP) Biotechnology $ 213 $ 215 $ 863 $ 864 Life Sciences 148 116 576 429 Diagnostics 47 49 192 198 Total Company $ 408 $ 380 $ 1,631 $ 1,491 Other Operating Profit Adjustments1 Biotechnology $ — $ 12 $ — $ 54 Life Sciences — 85 247 85 Diagnostics 99 23 99 23 Other — — — — Total Company $ 99 $ 120 $ 346 $ 162 Adjusted Operating Profit (non-GAAP)2 Biotechnology $ 721 $ 643 $ 2,548 $ 2,827 Life Sciences 524 436 1,702 1,723 Diagnostics 770 838 2,916 2,627 Other (83) (80) (326) (322) Total Company $ 1,932 $ 1,837 $ 6,840 $ 6,855 Three-Month Period Ended Year Ended December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 2 Adjusted Operating Profit (non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined). DANAHER CORPORATION Segment Sales, Operating Profit and Adjusted Operating Profit ($ in millions) 2 -- 4 of 21 -- Three-Month Period Ended December 31, 2024 Biotechnology Life Sciences Diagnostics Other Total Company Net Earnings from Continuing Operations (GAAP) $ 1,086 Interest, Net 47 Other Nonoperating (Income) Expense 63 Income Taxes 229 Operating Profit (GAAP) $ 508 $ 376 $ 624 $ (83) $ 1,425 Other Operating Profit Adjustments1 — — 99 — 99 Amortization of Intangible Assets 213 148 47 — 408 Adjusted Operating Profit (Non-GAAP)2 721 524 770 (83) 1,932 Depreciation 38 44 102 3 187 Adjusted EBITDA (Non-GAAP) $ 759 $ 568 $ 872 $ (80) $ 2,119 Interest, Net (47) Other Nonoperating Income (Expense) (63) Income Taxes (229) Other Operating Profit Adjustments1 (99) Amortization of Intangible Assets (408) Depreciation (187) Net Earnings from Continuing Operations (GAAP) $ 1,086 Sales (GAAP) $ 1,869 $ 2,032 $ 2,637 $ 6,538 Net Earnings from Continuing Operations Margin (GAAP) 16.6 % Operating Profit Margin (GAAP) 27.2 % 18.5 % 23.7 % 21.8 % Adjusted Operating Profit Margin (Non-GAAP)3 38.6 % 25.8 % 29.2 % 29.6 % Adjusted EBITDA Margin (Non-GAAP)4 40.6 % 28.0 % 33.1 % 32.4 % 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 2 Adjusted Operating Profit (non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined). 3 Adjusted Operating Profit Margin (Non-GAAP) is defined as Adjusted Operating Profit (Non-GAAP) divided by Sales (GAAP). 4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP). DANAHER CORPORATION Non-GAAP Profitability Measures ($ in millions) 3 -- 5 of 21 -- Three-Month Period Ended December 31, 2023 Biotechnology Life Sciences Diagnostics Other Total Company Net Earnings from Continuing Operations (GAAP) $ 1,121 Interest, Net (32) Other Nonoperating (Income) Expense 137 Income Taxes 111 Operating Profit (GAAP) $ 416 $ 235 $ 766 $ (80) $ 1,337 Other Operating Profit Adjustments1 12 85 23 — 120 Amortization of Intangible Assets 215 116 49 — 380 Adjusted Operating Profit (Non-GAAP)2 643 436 838 (80) 1,837 Depreciation 43 37 97 1 178 Adjusted EBITDA (Non-GAAP) $ 686 $ 473 $ 935 $ (79) $ 2,015 Interest, Net 32 Other Nonoperating Income (Expense) (137) Income Taxes (111) Other Operating Profit Adjustments1 (120) Amortization of Intangible Assets (380) Depreciation (178) Net Earnings from Continuing Operations (GAAP) $ 1,121 Sales (GAAP) $ 1,759 $ 1,930 $ 2,716 $ 6,405 Net Earnings from Continuing Operations Margin (GAAP) 17.5 % Operating Profit Margin (GAAP) 23.6 % 12.2 % 28.2 % 20.9 % Adjusted Operating Profit Margin (Non-GAAP)3 36.6 % 22.6 % 30.9 % 28.7 % Adjusted EBITDA Margin (Non-GAAP)4 39.0 % 24.5 % 34.4 % 31.5 % 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 2 Adjusted Operating Profit (non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined). 3 Adjusted Operating Profit Margin (Non-GAAP) is defined as Adjusted Operating Profit (Non-GAAP) divided by Sales (GAAP). 4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP). DANAHER CORPORATION Non-GAAP Profitability Measures ($ in millions) 4 -- 6 of 21 -- Year Ended December 31, 2024 Biotechnology Life Sciences Diagnostics Other Total Company Net Earnings from Continuing Operations (GAAP) $ 3,899 Interest, Net 161 Other Nonoperating (Income) Expense 56 Income Taxes 747 Operating Profit (GAAP) $ 1,685 $ 879 $ 2,625 $ (326) $ 4,863 Other Operating Profit Adjustments1 — 247 99 — 346 Amortization of Intangible Assets 863 576 192 — 1,631 Adjusted Operating Profit (Non-GAAP)2 2,548 1,702 2,916 (326) 6,840 Depreciation 151 167 394 9 721 Adjusted EBITDA (Non-GAAP) $ 2,699 $ 1,869 $ 3,310 $ (317) $ 7,561 Interest, Net (161) Other Nonoperating Income (Expense) (56) Income Taxes (747) Other Operating Profit Adjustments1 (346) Amortization of Intangible Assets (1,631) Depreciation (721) Net Earnings from Continuing Operations (GAAP) $ 3,899 Sales (GAAP) $ 6,759 $ 7,329 $ 9,787 $ 23,875 Net Earnings from Continuing Operations Margin (GAAP) 16.3 % Operating Profit Margin (GAAP) 24.9 % 12.0 % 26.8 % 20.4 % Adjusted Operating Profit Margin (Non-GAAP)3 37.7 % 23.2 % 29.8 % 28.6 % Adjusted EBITDA Margin (Non-GAAP)4 39.9 % 25.5 % 33.8 % 31.7 % 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 2 Adjusted Operating Profit (non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined). 3 Adjusted Operating Profit Margin (Non-GAAP) is defined as Adjusted Operating Profit (Non-GAAP) divided by Sales (GAAP). 4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP). DANAHER CORPORATION Non-GAAP Profitability Measures ($ in millions) 5 -- 7 of 21 -- Year Ended December 31, 2023 Biotechnology Life Sciences Diagnostics Other Total Company Net Earnings from Continuing Operations (GAAP) $ 4,221 Interest, Net (17) Other Nonoperating (Income) Expense 175 Income Taxes 823 Operating Profit (GAAP) $ 1,909 $ 1,209 $ 2,406 $ (322) $ 5,202 Other Operating Profit Adjustments1 54 85 23 — 162 Amortization of Intangible Assets 864 429 198 — 1,491 Adjusted Operating Profit (Non-GAAP)2 2,827 1,723 2,627 (322) 6,855 Depreciation 162 129 379 5 675 Adjusted EBITDA (Non-GAAP) $ 2,989 $ 1,852 $ 3,006 $ (317) $ 7,530 Interest, Net 17 Other Nonoperating Income (Expense) (175) Income Taxes (823) Other Operating Profit Adjustments1 (162) Amortization of Intangible Assets (1,491) Depreciation (675) Net Earnings from Continuing Operations (GAAP) $ 4,221 Sales (GAAP) $ 7,172 $ 7,141 $ 9,577 $ 23,890 Net Earnings from Continuing Operations Margin (GAAP) 17.7 % Operating Profit Margin (GAAP) 26.6 % 16.9 % 25.1 % 21.8 % Adjusted Operating Profit Margin (Non-GAAP)3 39.4 % 24.1 % 27.4 % 28.7 % Adjusted EBITDA Margin (Non-GAAP)4 41.7 % 25.9 % 31.4 % 31.5 % 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 2 Adjusted Operating Profit (non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined). 3 Adjusted Operating Profit Margin (Non-GAAP) is defined as Adjusted Operating Profit (Non-GAAP) divided by Sales (GAAP). 4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP). DANAHER CORPORATION Non-GAAP Profitability Measures ($ in millions) 6 -- 8 of 21 -- Three-Month Period Ended December 31, 2024 Sales Cost of sales Gross profit margin Operating profit Operating profit margin Earnings from continuing operations before income taxes Income taxes Net earnings from continuing operations for calculation of diluted earnings per common share Diluted net earnings per common share from continuing operations5 Reported (GAAP) $ 6,538 $ (2,648) 59.5 % $ 1,425 21.8 % $ 1,315 $ (229) $ 1,086 J $ 1.49 Amortization of acquisition-related intangible assetsA — — — 408 6.2 408 408 0.56 Fair value net (gains) losses on investmentsB — — — — — 64 64 0.09 ImpairmentsC — — — 43 0.7 43 43 0.06 Contract termination expenseF — — — 56 0.9 56 56 0.08 Tax effect of the above adjustmentsG (97) (97) (0.13) Discrete tax adjustmentsH (4) (4) (0.01) Adjusted (Non-GAAP) $ 6,538 $ (2,648) 59.5 % $ 1,932 29.6 % $ 1,886 $ (330) $ 1,556 $ 2.14 Three-Month Period Ended December 31, 2024 Sales Selling, general and administrative expenses Selling, general and administrative expenses as a % of sales Research and development expenses Research and development expenses as a % of sales Nonoperating income (expense), net (excluding interest) Interest income (expense), net Reported (GAAP) $ 6,538 $ (2,023) (30.9) % $ (442) (6.8) % $ (63) $ (47) Amortization of acquisition-related intangible assetsA — 408 6.2 — — — — Fair value net (gains) losses on investmentsB — — — — — 64 — ImpairmentsC — 43 0.7 — — — — Contract settlement expenseF — 56 0.9 — — — — Rounding — — (0.1) — — — — Adjusted (Non-GAAP) $ 6,538 $ (1,516) (23.2) % $ (442) (6.8) % $ 1 $ (47) 5 Diluted net earnings per common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding. DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 7 -- 9 of 21 -- Three-Month Period Ended December 31, 2023 Sales Cost of sales Gross profit margin Operating profit Operating profit margin Earnings from continuing operations before income taxes Income taxes Net earnings from continuing operations for calculation of diluted earnings per common share Diluted net earnings per common share from continuing operations5 Reported (GAAP) $ 6,405 $ (2,626) 59.0 % $ 1,337 20.9 % $ 1,232 $ (111) $ 1,121 J $ 1.50 Amortization of acquisition-related intangible assetsA — — — 380 5.9 380 380 0.51 Fair value net (gains) losses on investmentsB — — — — — 139 139 0.19 ImpairmentsC — — — 35 0.5 35 35 0.05 Acquisition-related itemsD — 8 0.1 95 1.5 95 95 0.13 Litigation gainsE — — — (10) (0.2) (10) (10) (0.01) Tax effect of the above adjustmentsG (131) (131) (0.18) Discrete tax adjustmentsH (71) (71) (0.10) Rounding — — — 0.1 — — — — Adjusted (Non-GAAP) $ 6,405 $ (2,618) 59.1 % $ 1,837 28.7 % $ 1,871 $ (313) $ 1,558 $ 2.09 Three-Month Period Ended December 31, 2023 Sales Selling, general and administrative expenses Selling, general and administrative expenses as a % of sales Research and development expenses Research and development expenses as a % of sales Nonoperating income (expense), net (excluding interest) Interest income (expense), net Reported (GAAP) $ 6,405 $ (2,035) (31.8) % $ (407) (6.4) % $ (137) $ 32 Amortization of acquisition-related intangible assetsA — 380 5.9 — — — — Fair value (gains) losses on investmentsB — — — — — 139 — ImpairmentsC — 35 0.5 — — — — Acquisition-related itemsD — 87 1.4 — — — — Litigation gainsE — (10) (0.2) — — — — Rounding — — 0.1 — — — — Adjusted (Non-GAAP) $ 6,405 $ (1,543) (24.1) % $ (407) (6.4) % $ 2 $ 32 5 Diluted net earnings per common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding. DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 8 -- 10 of 21 -- Year Ended December 31, 2024 Sales Cost of sales Gross profit margin Operating profit Operating profit margin Earnings from continuing operations before income taxes Income taxes Net earnings from continuing operations for calculation of diluted earnings per common share Diluted net earnings per common share from continuing operations6 Reported (GAAP) $ 23,875 $ (9,669) 59.5 % $ 4,863 20.4 % $ 4,646 $ (747) $ 3,899 J $ 5.29 Amortization of acquisition-related intangible assetsA — — — 1,631 6.8 1,631 1,631 2.21 Fair value net (gains) losses on investmentsB — — — — — 57 57 0.08 ImpairmentsC — — — 265 1.1 265 265 0.36 Acquisition-related itemsD — 25 0.1 25 0.1 25 25 0.03 Contract termination expenseF — — — 56 0.2 56 56 0.08 Tax effect of the above adjustmentsG (373) (373) (0.51) Discrete tax adjustmentsH (49) (49) (0.07) Rounding — — — — — — — — 0.01 Adjusted (Non-GAAP) $ 23,875 $ (9,644) 59.6 % $ 6,840 28.6 % $ 6,680 $ (1,169) $ 5,511 $ 7.48 Year Ended December 31, 2024 Sales Selling, general and administrative expenses Selling, general and administrative expenses as a % of sales Research and development expenses Research and development expenses as a % of sales Nonoperating income (expense), net (excluding interest) Interest income (expense), net Reported (GAAP) $ 23,875 $ (7,759) (32.5) % $ (1,584) (6.6) % $ (56) $ (161) Amortization of acquisition-related intangible assetsA — 1,631 6.8 — — — — Fair value net (gains) losses on investmentsB — — — — — 57 — ImpairmentsC — 265 1.1 — — — — Contract termination expenseF — 56 0.2 — — — — Rounding — — 0.1 — — — — Adjusted (Non-GAAP) $ 23,875 $ (5,807) (24.3) % $ (1,584) (6.6) % $ 1 $ (161) 6 For the year ended December 31, 2023, each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock for all periods presented prior to their conversion on April 17, 2023. Diluted net earnings per common share amounts for the relevant three-month periods may not add to the year- to-date amounts due to rounding. DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 9 -- 11 of 21 -- Year Ended December 31, 2023 Sales Cost of sales Gross profit margin Operating profit Operating profit margin Earnings from continuing operations before income taxes Income taxes Net earnings from continuing operations for calculation of diluted earnings per common share Diluted net earnings per common share from continuing operations6 Reported (GAAP) $ 23,890 $ (9,856) 58.7 % $ 5,202 21.8 % $ 5,044 $ (823) $ 4,200 J $ 5.65 Amortization of acquisition-related intangible assetsA — — — 1,491 6.2 1,491 1,491 2.00 Fair value net (gains) losses on investmentsB — — — — — 182 182 0.24 ImpairmentsC — 14 0.1 77 0.3 77 77 0.10 Acquisition-related itemsD — 8 — 95 0.4 95 95 0.13 Litigation gainsE — — — (10) — (10) (10) (0.01) Tax effect of the above adjustmentsG (354) (354) (0.47) Discrete tax adjustmentsH (47) (47) (0.06) MCPS "as if converted"I — — — — — — — 21 0.01 Rounding — — — — — — — — (0.01) Adjusted (Non-GAAP) $ 23,890 $ (9,834) 58.8 % $ 6,855 28.7 % $ 6,879 $ (1,224) $ 5,655 $ 7.58 Year Ended December 31, 2023 Sales Selling, general and administrative expenses Selling, general and administrative expenses as a % of sales Research and development expenses Research and development expenses as a % of sales Nonoperating income (expense) net (excluding interest) Interest income (expense), net Reported (GAAP) $ 23,890 $ (7,329) (30.7) % $ (1,503) (6.3) % $ (175) $ 17 Amortization of acquisition-related intangible assetsA — 1,491 6.2 — — — — Fair value net (gains) losses on investmentsB — — — — — 182 — ImpairmentsC — 63 0.3 — — — — Acquisition-related itemsD — 87 0.4 — — — — Litigation gainsE — (10) — — — — — Rounding — — (0.1) — — — — Adjusted (Non-GAAP) $ 23,890 $ (5,698) (23.9) % $ (1,503) (6.3) % $ 7 $ 17 6 For the year ended December 31, 2023, each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock prior to their conversion on April 17, 2023. Diluted net earnings per common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding. DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 10 -- 12 of 21 -- A Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above): Three-Month Period Ended Year Ended December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Pretax $ 408 $ 380 $ 1,631 $ 1,491 After-tax 338 317 1,346 1,226 B Net (gains) losses, including impairments, on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above): Three-Month Period Ended Year Ended December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Pretax $ 64 $ 139 $ 57 $ 182 After-tax 48 98 39 130 C Impairment charges related to a trade name in the Diagnostics segment recorded in the three-month period and year ended December 31, 2024 ($43 million pretax as reported in this line item, $32 million after-tax), a trade name in the Life Sciences segment recorded in the year ended December 31, 2024 ($222 million pretax as reported in this line item, $169 million after-tax), technology-based intangible assets in the Diagnostics segment recorded in the three-month period and year ended December 31, 2023 ($23 million pretax as reported in this line, $18 million after-tax) and technology-based intangible assets and other assets in the Biotechnology segment recorded in the three-month period and year ended December 31, 2023 ($12 million and $54 million pretax as reported in this line item, $8 million and $40 million after-tax, respectively). D Costs incurred for the fair value adjustment to inventory related to the acquisition of Abcam plc (“Abcam”) for the year ended December 31, 2024 ($25 million pretax as reported in this line item, $19 million after-tax). Transaction costs deemed significant, settlement of pre-acquisition share-based payment awards and fair value adjustments to inventory in each case related to the acquisition of Abcam in the three-month period and year ended December 31, 2023 ($95 million pretax as reported in this line item, $75 million after-tax). The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for the Company in a given period. E Gain related to settlement of litigation in the Life Sciences segment recorded in the three-month period and year ended December 31, 2023 ($10 million pretax as reported in this line, $8 million after-tax). F Loss on the termination of a commercial agreement in the Diagnostics segment in the three-month period and year ended December 31, 2024 ($56 million pretax as reported in this line item, $56 million after-tax). G This line item reflects the aggregate tax effect of all non-tax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. The MCPS dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends. DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 11 -- 13 of 21 -- H Discrete tax adjustments and other tax-related adjustments for the three-month period ended December 31, 2024, include the impact of net discrete tax benefits of $4 million due principally to net discrete tax benefits resulting from the release of reserves for uncertain tax positions due to the expiration of statutes of limitation and changes in estimates related to prior year tax filing positions, net of charges related to changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2024 include the impact of net discrete tax benefits of $49 million due principally to net discrete tax benefits resulting from excess tax benefits from stock compensation, the release of reserves for uncertain tax positions due to the expiration of statutes of limitation and changes in estimates related to prior year tax filing positions, net of charges related to changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments for the three-month period ended December 31, 2023, include the impact of net discrete tax benefits of $71 million due principally to net deferred tax benefits resulting from changes in estimates related to prior year tax filing positions and the release of reserves for uncertain tax positions due to the expiration of statutes of limitation, net of charges related to changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2023 include the impact of net discrete tax benefits of $47 million due principally to net discrete tax benefits from changes in estimates related to prior year tax filing positions, the release of reserves for uncertain tax positions due to the expiration of statutes of limitation and excess tax benefits from stock-based compensation, net of charges related to tax costs related to the separation of Veralto Corporation, tax costs from legal and operational actions undertaken to realign certain of its businesses and changes in estimates associated with prior period uncertain tax positions. The Company anticipates excess tax benefits from stock compensation of approximately $7 million per quarter and therefore excludes benefits in excess of this amount in the calculation of adjusted diluted net earnings from continuing operations per common share. I In May 2020, the Company issued $1.72 billion in aggregate liquidation preference of 5.0% MCPS. Dividends on the MCPS were payable on a cumulative basis at an annual rate of 5.0% on the liquidation preference of $1,000 per share. Each share of MCPS converted on April 17, 2023 into 5.0175 shares of Danaher’s common stock. For the calculation of net earnings per common share from continuing operations, the impact of the dilutive MCPS is calculated under the “if-converted” method and the related MCPS dividends are excluded. For the purposes of calculating adjusted earnings per common share from continuing operations, the Company has excluded the paid MCPS cash dividends and assumed the “if-converted” method of share dilution (the incremental shares of common stock deemed outstanding applying the “if-converted” method of calculating share dilution only with respect to any MCPS the conversion of which would be dilutive in the particular period are referred to as the “Converted Shares”) for any MCPS that were anti-dilutive for the given period. For additional information about the impact of the MCPS on the calculation of diluted EPS, see note 7 in the Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding table below. J Net earnings from continuing operations for calculation of diluted earnings per common share is summarized as follows ($ in millions): Three-Month Period Ended Year Ended December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Net earnings from continuing operations $ 1,086 $ 1,121 $ 3,899 $ 4,221 MCPS dividends — — — (21) Net earnings from continuing operations attributable to common stockholders for Basic and Diluted EPS $ 1,086 $ 1,121 $ 3,899 $ 4,200 DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 12 -- 14 of 21 -- Three-Month Period Ended Year Ended December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Average common stock and common equivalent shares outstanding - diluted (GAAP) 7 728.2 746.1 737.2 743.1 Converted shares 8 — — — 2.5 Adjusted average common stock and common equivalent shares outstanding - diluted (non-GAAP) 728.2 746.1 737.2 745.6 7 The impact of the MCPS calculated under the if-converted method was anti-dilutive for the year ended December 31, 2023 and as such, approximately 2.5 million shares underlying the MCPS were excluded from the calculation of diluted EPS for the period and the related MCPS dividends of $21 million were included in the calculation of net earnings for diluted EPS for the period. As of April 17, 2023, all outstanding shares of the MCPS converted into 8.6 million shares of the Company’s common stock. 8 The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using the actual conversion rates as of December 31, 2023. DANAHER CORPORATION Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding (shares in millions) 13 -- 15 of 21 -- Segments Total Company Biotechnology Life Sciences Diagnostics Three-Month Period Ended December 31, 2023 Operating Profit Margins from Continuing Operations (GAAP) 20.90 % 23.60 % 12.20 % 28.20 % Fourth quarter 2024 impact from operating profit margins of businesses that have been owned for less than one year (0.70) — (1.80) 0.85 Fourth quarter 2024 loss on the termination of a commercial arrangement in the Diagnostics segment (0.85) — — (2.15) Fourth quarter 2023 transaction costs deemed significant, settlement of pre-acquisition share-based payment awards and fair value adjustments to inventory, in each case related to the acquisition of Abcam 1.50 — 4.90 — Fourth quarter 2024 impairment charge related to a trade name in the Diagnostics segment net of fourth quarter 2023 impairment charges related to technology-based intangible assets in the Diagnostics segment and technology-based intangible assets and other assets in the Biotechnology segment (0.10) 0.70 — (1.65) Fourth quarter 2023 gain from the resolution of a litigation contingency in the Life Sciences segment (0.15) — (0.55) — Year-over-year core operating profit margin changes for the fourth quarter 2024 (defined as all year-over-year operating profit margin changes other than the changes identified in the line items above) (non-GAAP) 1.20 2.90 3.75 (1.55) Three-Month Period Ended December 31, 2024 Operating Profit Margins from Continuing Operations (GAAP) 21.80 % 27.20 % 18.50 % 23.70 % Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for the Company in a given period. DANAHER CORPORATION Operating Profit Margins and Year-Over-Year Core Operating Margin Changes 14 -- 16 of 21 -- Segments Total Company Biotechnology Life Sciences Diagnostics Year Ended December 31, 2023 Operating Profit Margins from Continuing Operations (GAAP) 21.80 % 26.60 % 16.90 % 25.10 % Full year 2024 impact from operating profit margins of businesses that have been owned for less than one year (0.85) — (2.45) — Full year 2023 transaction costs deemed significant, settlement of pre-acquisition share- based payment awards and fair value adjustments to inventory, net of full year 2024 acquisition-related fair value adjustment to inventory, in each case related to the acquisition of Abcam 0.30 — 1.00 — Full year 2024 impairment charges related to a trade name in each of the Life Sciences and Diagnostics segments, net of full year 2023 impairment charges related to technology-based intangible assets in the Diagnostics segment and technology-based intangible assets and other assets in the Biotechnology segment (0.75) 0.75 (3.05) (0.20) Full year 2024 loss on the termination of a commercial arrangement in the Diagnostics segment (0.25) — — (0.60) Full year 2023 gain from the resolution of a litigation contingency in the Life Sciences segment (0.05) — (0.15) — Year-over-year core operating profit margin changes for full year 2024 (defined as all year-over-year operating profit margin changes other than the changes identified in the line items above) (non-GAAP) 0.20 (2.45) (0.25) 2.50 Year Ended December 31, 2024 Operating Profit Margins from Continuing Operations (GAAP) 20.40 % 24.90 % 12.00 % 26.80 % Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for the Company in a given period. DANAHER CORPORATION Operating Profit Margins and Year-Over-Year Core Operating Margin Changes 15 -- 17 of 21 -- Three-Month Period Ended Year-over-Year Change Year Ended Year-over-Year Change December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Total Cash Flows from Continuing Operations: Total cash provided by operating activities from continuing operations (GAAP) $ 2,019 $ 1,591 $ 6,688 $ 6,490 Total cash used in investing activities from continuing operations (GAAP) $ (694) $ (6,017) $ (1,981) $ (7,048) Total cash (used in) provided by financing activities from continuing operations (GAAP) $ (1,692) $ (1,819) $ (8,385) $ 154 Free Cash Flow from Continuing Operations: Total cash provided by operating activities from continuing operations (GAAP) $ 2,019 $ 1,591 ~27.0 % $ 6,688 $ 6,490 ~3.0 % Less: payments for additions to property, plant & equipment (capital expenditures) from continuing operations (GAAP) (516) (434) (1,392) (1,383) Plus: proceeds from sales of property, plant & equipment (capital disposals) from continuing operations (GAAP) 1 6 13 12 Free cash flow from continuing operations (non-GAAP) $ 1,504 $ 1,163 ~29.5 % $ 5,309 $ 5,119 ~3.5 % Operating Cash Flow to Net Earnings Ratio (GAAP) Total cash provided by operating activities from continuing operations (GAAP) $ 2,019 $ 1,591 $ 6,688 $ 6,490 Net earnings from continuing operations (GAAP) $ 1,086 $ 1,121 $ 3,899 $ 4,221 Operating cash flow from continuing operations to net earnings from continuing operations conversion ratio 1.86 1.42 1.72 1.54 Free Cash Flow to Net Earnings Ratio (non-GAAP) Free cash flow from continuing operations from above (non-GAAP) $ 1,504 $ 1,163 $ 5,309 $ 5,119 Net earnings from continuing operations (GAAP) $ 1,086 $ 1,121 $ 3,899 $ 4,221 Free cash flow from continuing operations to net earnings from continuing operations conversion ratio (non-GAAP) 1.38 1.04 1.36 1.21 The Company defines free cash flow as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”). All amounts presented above reflect only continuing operations. DANAHER CORPORATION Cash Flow from Continuing Operations, Free Cash Flow from Continuing Operations, Operating Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Ratio and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Conversion Ratio ($ in millions) 16 -- 18 of 21 -- Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the corresponding GAAP measure, help our investors: • with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers; • with respect to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; and • with respect to free cash flow from continuing operations and related non-GAAP cash flow measures (the “FCF Measure”), understand Danaher’s ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company’s debt service requirements and other non- discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures). Management uses the non-GAAP measures referenced above to measure the Company’s operating and financial performance, and uses core sales and non- GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations and the FCF Measure in the Company’s executive compensation program. • The items excluded from the non-GAAP profitability measures set forth above have been excluded for the following reasons: ◦ Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized. ◦ Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time. ◦ Other Adjustments: With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult. • With respect to adjusted average common stock and common equivalent shares outstanding, Danaher’s MCPS mandatorily converted into Danaher common stock on the mandatory conversion date of April 17, 2023 (unless converted or redeemed earlier in accordance with the terms of the applicable certificate of designations). With respect to the calculation of Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we apply the “if converted” method of share dilution to the MCPS in all applicable periods irrespective of whether such preferred shares were dilutive or anti-dilutive in the period. We believe this presentation provides useful information to investors by helping them understand the net impact on Danaher’s earnings per share-related measures irrespective of the period. DANAHER CORPORATION Statement Regarding Non-GAAP Measures 17 -- 19 of 21 -- • With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to “restructuring charges” and “other adjustments”, we exclude the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued operations) because the timing, size, number and nature of such transactions can vary significantly from period to period and may obscure underlying business trends and make comparisons of long-term performance difficult. • We calculate adjusted EBITDA by adding to operating profit amounts equal to depreciation and amortization and making the other adjustments reflected in the applicable tables above, which allows us to calculate and disclose such measure by segment. Given Danaher’s diversification, we believe this helps our investors compare the profitability of our individual segments to peer companies with like business lines. • With respect to core sales, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult. • With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements. The Company provides forecasted sales only on a non-GAAP basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines. Additionally, we do not reconcile forecasted adjusted operating profit margin (or components thereof) to the comparable GAAP measures because of the difficulty in estimating the other components (in addition to items identified in the prior sentence) such as investment gains and losses and impairments, which would be reflected in any forecasted GAAP operating profit. DANAHER CORPORATION Statement Regarding Non-GAAP Measures 18 -- 20 of 21 -- 19 -- 21 of 21 --